Pharmacoepidemiologic, Clinical, and Microbiological Study on Antimicrobial Therapy of Inflammatory Diseases of Maxillofacial Area

Clinical Microbiology and Antimicrobial Chemotherapy. 2011; 13(4):360-367

Type
Journal article

Abstract

This paper presents the results of a study to evaluate pharmacological therapy in inflammatory diseases of maxillofacial area in outpatient and hospital settings. The study included a review of medical records for outpatients (n = 600) and hospitalized patients (n = 200) with inflammatory diseases of maxillofacial area, and questioning of the dental surgeons (n = 43) on etiology and treatment of those diseases. Identification of major pathogens and their antimicrobial susceptibility testing were also performed in a total of 107 patients (aged 18 to 63 years). The dental surgeons most frequently prescribed doxycycline in outpatient settings, and oxacillin, ampicillin, metronidazole, and lincomycin in hospitalized patients. Staphylococci, streptococci, and anaerobes were considered by dentist surgeons as the leading pathogens of inflammatory diseases of maxillofacial area. The main reported criteria for the choice of empirical antimicrobial treatments were an activity against presumptive pathogen(s) and a good tolerability. A total of 51 and 101 causative microorganisms were isolated from 30 outpatients and 77 hospitalized patients with inflammatory diseases of maxillofacial area, respectively; the most predominant pathogens were streptococci and staphylococci (depending on the clinical form of disease). All S. aureus isolates were susceptible to oxacillin, vancomycin, erythromycin, clindamycin, and ciprofloxacin.

Views
0 Abstract
0 PDF
0 BibTeX
Shared
0
0
0
0
0
0